Inventor · disambiguated record
Ashish Kalra
Also filed as: KALRA ASHISH
2 granted patents·9 pending applications·10 citations·filing 2014–2025
57Inventor score
Files withIPSEN BIOPHARM LTD5SCHOLAR ROCK INC4MERRIMACK PHARMACEUTICALS INC1MERRIRNACK PHARMACEUTICALS INC1
Top patents by PatentIndex Score
11 records- 0190US11344552B2Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatinIPSEN BIOPHARM LTD·Filed 2017·Granted May 31, 2022·4 cites·15 claims
- 0287US11071726B2Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)IPSEN BIOPHARM LTD·Filed 2017·Granted Jul 27, 2021·6 cites·21 claims
- 0383US2024358706A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2024·Application pending·0 cites
- 0478US2024016928A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2023·Application pending·0 cites
- 0577US2025381191A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2025·Application pending·0 cites
- 0675US2023062425A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2022·Application pending·0 cites
- 0764US2019209682A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2019·Application pending·0 cites
- 0860US2018207267A1Isoform-specific, context-permissive tgfb1 inhibitors and use thereofSCHOLAR ROCK INC·Filed 2018·Application pending·0 cites
- 0955US2014170075A1Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agentsMERRIRNACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1054US2017049775A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1150US2023050148A1Tgf-beta inhibitors and use thereofSCHOLAR ROCK INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ashish Kalra files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →